CRLF2 and acute lymphoblastic leukemia: Recent studies have identified that BET inhibition can reverse CRLF2 overexpression in early T-cell precursor acute lymphoblastic leukemia (ETP-ALL) cell lines, suggesting a link with PRC2 dysfunction [77].